Avelumab and Merkel Cell Carcinoma: Legal Considerations for Michigan Patients
From General Health Guidance to Occupational Risk Awareness
For decades, public health communication has centered on accessible, general wellness guidance—from managing seasonal influenza to navigating primary care during a pandemic. This legacy of clear, precautionary information has helped communities recognize when to seek medical attention for common illnesses. Yet as industrial processes have expanded, so too has the need to extend that same clarity into occupational and environmental health contexts. Workers in mass production settings may encounter substances not typically addressed in routine health advisories. One such area involves exposure to certain therapeutic agents during manufacturing, where the line between medical treatment and workplace hazard can blur. For example, individuals handling pharmaceutical compounds like avelumab should be aware of potential long-term health considerations, including rare but serious conditions such as Merkel cell carcinoma. While general health resources remain vital for everyday concerns, they may not cover the specific risks associated with occupational exposure to biologics. This gap underscores the importance of consulting specialized legal counsel—particularly a Michigan attorney familiar with both state workers’ compensation law and emerging pharmaceutical liability—when a worker suspects a link between their job duties and a subsequent cancer diagnosis.
Understanding Avelumab and Its Role in Merkel Cell Carcinoma
Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Despite these advances, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors (ICIs) such as avelumab do not respond or eventually progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, ICIs can cause immune-related adverse events (irAEs) due to overactivation of the immune system, including cases of hypercalcaemia secondary to reactivation of sarcoidosis during avelumab treatment (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other mechanisms of resistance include down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).
Merkel Cell Carcinoma: Risk Factors and Clinical Presentation
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the virus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence of MCC is rising, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Clinical presentation typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often on the head, neck, or extremities. Diagnosis is confirmed by histopathology and immunohistochemistry, including markers such as cytokeratin 20 and neuroendocrine markers. For patients with metastatic MCC, avelumab is a standard first-line or later-line therapy, but for those who become refractory to avelumab, treatment options are limited. A retrospective study at three German academic sites found that five patients with avelumab-refractory metastatic MCC were subsequently treated with combined ipilimumab and nivolumab, and three of five responded according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study confirmed that about 50% of patients with advanced MCC treated with ICI progress on therapy, highlighting the need for alternative strategies (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Legal Considerations for Patients Treated with Avelumab
From a risk perspective, patients who have been treated with avelumab for Merkel cell carcinoma and experienced adverse outcomes—such as lack of response, disease progression, or severe immune-related adverse events—may have legal considerations regarding the adequacy of warnings provided by the manufacturer. The prescribing information for avelumab includes warnings about immune-mediated adverse reactions, but patients and attorneys may evaluate whether these warnings were sufficient to inform patients and healthcare providers of the specific risks, including the possibility of treatment failure or irAEs. The timeline between exposure to avelumab and documented harm is critical: for example, hypercalcaemia due to sarcoidosis reactivation occurred during treatment and resolved with corticosteroids while avelumab was continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). In cases of disease progression, the timeline may span weeks to months after initiation of therapy, as response rates are approximately one-third and many patients do not respond (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients in Michigan who have experienced harm potentially linked to avelumab, consulting an attorney may be appropriate to assess whether the manufacturer’s warnings were adequate and whether there is a basis for a product liability claim. Attorneys would need to review medical records, treatment history, and the specific adverse events or lack of efficacy experienced, as well as the timing relative to avelumab administration. The rarity of MCC and the limited approved therapies may also influence legal arguments regarding the risk-benefit balance presented to patients. In summary, avelumab is an important but imperfect treatment for metastatic Merkel cell carcinoma, with a significant proportion of patients not responding or experiencing immune-related adverse events. Patients in Michigan who have suffered harm may wish to consult an attorney to evaluate the adequacy of warnings and the specific circumstances of their case.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
What is avelumab and how is it used in Merkel cell carcinoma?
Avelumab (Bavencio®) is a monoclonal antibody that targets PD-L1 and is approved for treating metastatic Merkel cell carcinoma (MCC). It works by blocking the PD-L1 protein, helping the immune system attack cancer cells. Approval was based on the JAVELIN Merkel 200 trial, which showed objective responses in about one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).
When should a Michigan patient consult an attorney about avelumab?
A Michigan patient should consult an attorney if they have been treated with avelumab for Merkel cell carcinoma and experienced harm such as lack of response, disease progression, or severe immune-related adverse events. An attorney can evaluate whether the manufacturer’s warnings were adequate and whether a product liability claim is warranted. The rarity of MCC and limited treatment options may also be relevant.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.